APLS

Apellis Pharmaceuticals

The company develops and commercialises therapeutic compounds targeting the complement system for patients with haematological, ophthalmological and rare kidney diseases.

AUPH

The company develops and provides pharmaceutical therapies for adult patients living with autoimmune diseases such as active lupus nephritis.

Annexon Biosciences

This biopharmaceutical company develops complement-based therapies for patients with autoimmune, neurodegenerative and ophthalmic diseases of the body, brain and eye.

ArgenX

This company develops and commercialises antibody-based therapies to treat patients suffering from severe autoimmune diseases and cancer.

Alpine Immune

This company develops protein-based immunotherapies for patients with autoimmune and inflammatory diseases, such as IgA nephropathy and systemic lupus erythematosus.

Alpine Immune Sciences

This biopharmaceutical company develops protein-based immunotherapies to treat autoimmune and inflammatory diseases for patients with conditions like kidney disease.

ALMS

This biopharmaceutical company develops oral therapies to treat patients with immune-mediated diseases, neuroinflammatory conditions and neurodegenerative disorders.

Apitope

Apitope develops antigen-specific peptide therapeutics to treat autoimmune diseases and allergies for patients requiring targeted immunotherapy and immune tolerance restoration.